Valbenazine (US Brand name Ingrezza®) is a vesicular monoamine transporter 2 (VMAT2) inhibitor. Here is basic information about this medication.
FDA-approved indications
Treatment of adults with tardive dyskinesia
Dosage
The initial dose is 40 mg once daily orally. After one week, increase the dose to the recommended dose of 80 mg once daily.
Administration and instructions
Valbenazine may be administered with or without food.
In patients with moderate and severe hepatic impairment, recommended dose is 40 mg daily.
Based on tolerability, consider dose reduction for known poor CYP2D6 metabolizers.
Dosage forms and strengths
Capsules: 40 mg and 80 mg
Please refer to Prescribing Information (see link below) for complete discussion of dosage, administration, warnings and precautions, contraindications, etc.
Related Pages
Prescribing Information for valbenazine (Ingrezza®)
Potential side effects of valbenazine (Ingrezza®) handout
Comparing the VMAT2 inhibitors
Valbenazine (Ingrezza®) and VMAT2
Copyright 2017, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons, or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.
Leave a Reply: